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In the present study the endotoxin-neutralizing capacity of human plasma obtained from healthy volunteers was determined by use of the limulus- 
amebocyte-lysate st. The extent of the endotoxin-neutralizing capacity which showed a very broad variation was correlated to the plasma levels 
of some proteins which are believed to contribute to endotoxin transport and detoxification. The plasma levels of a,-macroglobulin and transferrin, 
the major transport proteins, as well as the levels of IgG, IgA and IgM and apoprotein A were not significantly correlated to the neutralizing 
capacity. Only the apoprotein B, the major apoprotein of the low density lipoprotein fraction shows a significant correlation. Together with pre- 
viously published results it should be concluded that low density lipoproteins are involved in the endogenous endotoxin-neutralizing reaction occur- 
ing in human plasma, at least when high doses of endotoxin are administered. Nevertheless the endotoxin-neutralizing reaction seems to be a very 
complex multistep process. 
Endotoxin neutralization; Plasma; Plasma protein 
1. INTRODUCTION 
Endotoxins (lipopolysaccharide; LPS) are believed to 
represent the main pathogenetic mediators of Gram- 
negative bacteria [ 1,2]. The clinical symptoms of Gram- 
negative sepsis can be reproduced either by bacteria or 
endotoxin which is a major constituent of the cell wall 
of these bacteria [3]. Although bacteremia can be 
treated by antibiotics, very little knowledge exists about 
antiendotoxic agents. On the other hand, plasma is 
known to, be a very potent endotoxin inhibitor [5]. In 
order to elucidate the nature of the endotoxin-inhibiting 
factors of human plasma, one approach is the charac- 
terization of the endotoxin-binding plasma consti- 
tuents. The main endotoxin carrier system in blood is 
believed to be represented by the high density lipopro- 
tein fraction [6,7]. Although some aspects of the LPS 
toxicity could be inhibited by the high density lipopro- 
teins in vitro and in vivo, HDL-complexed LPS re- 
tained the ability to induce hypotension and death in a 
rabbit shock model [8,9]. Hypotension and death, 
however, could be prevented by lipoprotein-free serum 
fractions. In 1977, Johnson et al. described a plasma 
protein which is able to neutralize endotoxin in vivo 
[lo]. A further characterization of this protein was not 
possible at that time. Flegel et al. [ll] were able to 
demonstrate the inhibition of the endotoxin-induced 
release of tumor necrosis factor from isolated mono- 
cytes by human low density lipoproteins. To our 
knowledge there are no further in vivo studies concern- 
ing a possible benefit of the low density lipoproteins in 
preventing hypotension and death in the endotoxic 
shock. In 1987, the endotoxin-binding capacity of 
human transferrin and Gc globulin was demonstrated 
[ 121. Furthermore, crz-macroglobulin was shown to 
bind endotoxin in a specific manner [ 131. In a prospec- 
tive clinical study we demonstrated a strong correlation 
between the plasma levels of these proteins and the out- 
come of Gram-negative sepsis [14]. As shown by use of 
the limulus-amebocyte-lysate test, the endotoxin- 
neutralizing capacity of human plasma could be en- 
hanced by addition of these endotoxin-binding proteins 
[ 151. In order to obtain further information about the 
nature of the endotoxin-neutralizing capacity of human 
plasma, we developed a new method for determining 
the endotoxin-neutralizing capacity by the limulus- 
amebocyte-lysate t st and tried to correlate the neutral- 
izing activity with the levels of the described proteins 
presumed to be involved in the neutralizing reaction. 
2. MATERIALS AND METHODS 
Correspondence address: D. Berger, Department of General Surgery, 
University of Ulm, Steinhoevelstrasse 9, 7900 Ulm, Germany 
From 39 healthy volunteers blood was taken by puncture of the 
cubital vein under sterile conditions. The coagulation system of the 
samples was inhibited by the addition of 15 IE heparin/ml blood. 
Platelet-poor plasma was prepared by immediate centrifugation at 
2000 x g for 15 min. The samples were stored for one week at - 20°C. 
before determining the endotoxin-neutralizing capacity and the pro- 
tein levels. 
The plasma levels of transferrin, crz-macroglobulin, apoprotein A, 
apoprotein B, IgG, IgM, IgA, haptoglobin and cri-acid glycoprotein 
were determined nephelometrically by use of the Bering nephelometer 
Analyser 100 (Behring Co., Marburg, Germany). Antisera as well as 
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further buffers needed for the nephelometric determinations were 
also purchased from Behring Co. The inter- and intra-assay variation 
coefficients were in the range of 5% for all proteins tested. 
The limulus-amebocyte-lysate test was delivered from Byk-Sangtec 
(Dietzenbach, Germany), together with the endotoxin standard, 
which is adjusted to the EC 5 standard of US Food and Drug Ad- 
ministration. The test itself was performed as a chromogenic two-step 
assay and endpoints were determined in microtiter plates (Greiner 
Co., Niirtingen, Germany). The chromogenic substrate, Pefachrome, 
was obtained from Pentapharm Co. (Basel, Switzerland). 
The following solutions were used in the limulus-amebocyte-lysate 
test: 
Solution A: lysate, solubilized in pyrogen free water according to the 
recommendations of the manufacturer 
Solution B: chromogenic substrate, 10 pmol in 6.6 ml Hz0 
Solufion C: buffer, 0.05 mol/l Tris-HCl, pH 9.0, containing 0.2 mol/l 
NaCl 
Solution D: acetic acid 20% 
50 ~1 of the sample were incubated with 50 pl of the lysate for 25 min 
at 37°C. Afterwards 100 pl of the chromogenic substrate (solution B 
diluted 1:2 with solution C) was added and further incubated at 37°C 
for three min. The reaction was stopped by adding 200 ~1 solution D. 
The color formed, p-nitroaniline, was quantified at 405 nm in a spec- 
trophotometer of SLT Co. (Salzburg, Austria), suitable for microtiter 
plates. The endotoxin content of unknown samples was determined 
according to a standard curve which was set up in parallel. Linearity 
was obtained from 0.06 EU/ml to 0.6 EU/ml. 
In order to follow up the endotoxin-neutralizing capacity of 
plasma, 20 pl of the NP2 standard (lipopolysaccharide of Sulmonellu 
abortus equi, 100 ng/ml corresponding to 1000 EU/ml) were added to 
180 ~1 plasma and incubated for 60 min at 24°C. After dilution 1:lO 
with isotonic sodium chloride the endotoxin content was determined 
according to the standard curve, without further inactivation, usually 
performed when the endotoxin content of biological samples should 
be determined. Time sequence studies showed that maximal inactiva- 
tion was achieved after 20 min and did not change any more for up 
to 24 h. 
The endotoxin content of the 1: 10 diluted sample amounted to 10 
EU/ml. The endotoxin recovery ranged from 0.15 to 0.6 EU/ml; 
these values are given in Fig. 1. 
3. RESULTS AND DISCUSSION 
For a long time plasma has been known to be a very 
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Fig. 1. Linear correlation between the endotoxin recovery and the 
plasma level of apoprotein B. The ordinate shows the endotoxin 
recovery in EU/ml, on the abscissa the plasma levels of apoprotein B 
are depicted. The endotoxin content of the sample amounted to 10 
EU/ml. 
potent endotoxin inhibitor [5,16]. Although there are 
some hints concerning the nature of the endotoxin- 
inhibiting plasma constituents, experimental studies 
yielded quite inconsistent results. Up to now the main 
endotoxin carrier system seems to be represented by the 
high density lipoproteins [6,7]. This lipoprotein frac- 
tion, however, could not diminish the endotoxin- 
induced hypotension in animals [9]. On the contrary, 
this capacity was found in a lipoprotein-free serum 
fraction. Other authors also demonstrated endotoxi- 
city-influencing action in lipoprotein-free protein frac- 
tions [10,15]. Summarizing these data, there is no 
generally accepted hypothesis concerning the nature of 
the endotoxin detoxification process in plasma. In 
order to contribute to the solution of this question 
which is obviously of major clinical importance we 
developed a test to determine the endotoxin-neutral- 
izing capacity based on the limulus-amebocyte-lysate 
test. The principle of our test simply consists in adding 
endotoxin to plasma and determining the endotoxin 
recovery without any further inactivation. Warren et al. 
demonstrated in 1985 that the limulus-amebocyte-lysate 
test is a simple method in order to determine the 
endotoxin-neutralizing capacity. In a turbidimetric 
assay they found the neutralizing capacity as determin- 
ed in the LAL test correlated to the antipyrogenic activi- 
ty in the rabbit fever test, so that a direct effect of 
plasma on the enzymatic cascade of the limulus lysate 
seems to be improbable [17]. By use of this assay the 
endotoxin-inactivating capacity of plasma samples of 
39 healthy volunteers was determined. There was no 
correlation to sex or age, although the absolute value of 
recovery varies from below 0.15 EU/ml to 0.6 EU/ml. 
Recently we described endotoxin-binding capacity of 
human transferrin and az-macroglobulin [ 12,131. Ac- 
cording to the previously cited studies, also the high 
density lipoprotein fraction or the low density lipopro- 
teins seem to be involved in the endotoxin transport. In 
order to elucidate a relationship between the endotoxin 
neutralization and the plasma constituents we determin- 
ed the plasma levels of transferrin, cY2-macroglobulin, 
apoprotein A, and apoprotein B. Furthermore the 
levels of the acute phase reactants al-acid glycoprotein 
and haptoglobin were determined in order to exclude 
any stress reaction which would be seen as an increase 
of the plasma levels. In all samples no increase above 
the normal range could be observed. Also the volun- 
teers did not report any signs of disease in the last 4 
weeks. 
The acute phase reactants haptoglobin and cri-acid 
glycoprotein did not correlate to the endotoxin-neutral- 
izing capacity (results not demonstrated). The same fact 
passes for transferrin and az-macroglobulin (Table I). 
As would be expected, also the plasma levels of IgG, 
IgA and IgM did not show any correlation. Although 
transferrin and az-macroglobulin possess a high affini- 
ty to endotoxin [13], a contribution to the neutralizing 
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Apo A 
Table I 
Correlation coefficients and statistical significance 
Apo B Transferrin cY2-macroglobulin IgG IgM IgA Apo B 
(reciorocal correlation) . . 
Correlation coefficient 0.005 -0.33 0.16 - 0.05 -0.18 -0.11 -0.17 0.47 
P< 0.97 0.04 0.3 0.79 0.27 0.52 0.3 0.003 
The table demonstrates the coefficients of a linear correlation between the levels of the different proteins and the endotoxin recovery. Furthermore 
the P value is given. As to the case of the plasma levels of apoprotein B, a reciprocal correlation (l/y = ax + b) was tested and a highly significant 
result obtained was also demonstrated. The high coefficient of the reciprocal correlation implies that the correlation is not a linear one. Obviously 
the same differences of the concentration of apoprotein B at very low protein levels lead to a greater difference of the endotoxin-neutralizing capaci- 
ty, as the same differences of the protein concentration in the higher concentration range of apoprotein B. 
activity seems to be ruled out, at least in the assay used 
in this study. These results are also in contrast with a 
clinical study, in which a strong correlation between the 
plasma levels of transferrin and az-macroglobulin and 
the outcome of Gram-negative sepsis was demonstrated 
[14]. Also, an experimental study was able to show an 
endotoxicity-influencing effect of transferrin. 
However, it should be taken into account that the en- 
dotoxin concentrations found in plasma of septic pa- 
tients, are in the pg/ml range, as well as the endotoxin 
concentrations which were used in the previous study 
showing that the influence of transferrin on endotoxi- 
city was quite low [19]. In the assay used in the present 
study, ng amounts of endotoxin were added to plasma. 
So an explanation of these inconsistent results could be 
that at low endotoxin concentrations an inhibiting ef- 
fect is possible or even probable. At pharmacological 
doses both proteins cannot contribute to the neutraliz- 
ing action. 
The Ig classes also did not exhibit any correlation 
with the endotoxin-neutralizing activity. Perhaps these 
results obtained for the immunoglobulins could be ex- 
plained in an analogous way. Furthermore the blood 
was obtained from healthy volunteers, and not after im- 
munization with endotoxin. Experimental studies that 
showed an anti-endotoxic effect of the immunoglobulin 
fractions were usually performed with hyperimmune 
sera [20,21]. Warren et al. also demonstrated the lack of 
immunoglobulins and some other serum proteins in a 
system similar to that one used in our experiments to 
contribute to the endotoxin-neutralizing capacity [ 171. 
They did not find a correlation with the levels of an- 
tilipid A antibodies, since the levels of these specific im- 
munoglobulins found in non-immunized men are very 
low. This protein class would be expected not to con- 
tribute to the inactivation process in our system. As to 
the case of apoprotein A, there is also no correlation, 
which is in good agreement with the results of Abdel- 
noor et al. who showed the lack of endotoxin-neutral- 
izing activity of high density lipoproteins in vivo [9]. 
The only correlation betwen the neutralizing activity 
and the serum level of a protein was observed in the case 
of apoprotein B (Fig. 1). This correlation is quite low, 
as can be seen in Table I and also in Fig. 1, where the 
serum levels of the protein are given on the abscissa nd 
the endotoxin recovery is depicted on the ordinate. The 
correlation is a negative one, meaning that the higher 
the endotoxin recovery, the lower the protein levels 
determined. Similar results were reported by Flegel et 
al. [l l] who used isolated monocytes. They found that 
the inhibition of the endotoxin-induced release of 
tumor necrosis factor from isolated monocytes depends 
on the low density lipoproteins because LDL-free serum 
exhibited no inhibition of the TNF release. These 
authors described the necessity to incubate serum with 
endotoxin for at least 3 h, in order to see any effect. In 
our system we tested different incubation times between 
plasma and endotoxin from 20 min to 24 h and found 
maximal inactivation already after 20 min. Shorter in- 
cubation times were not studied because this parameter 
should be considered with caution. The inactivation 
process was not stopped before the samples were 
diluted and added to the limulus-amebocyte-lysate t st. 
So during the 35 min of incubation between sample and 
lysate the inactivation process can go on. Nevertheless, 
in our system the inactivation seems to run off much 
faster than in the monocyte system. In spite of this, the 
correlation in our assay is in principal in accordance 
with the cell culture study. 
The main question arising from our results, however, 
is: is there any physiological significance of the LDL- 
endotoxin interaction? As described above, the endo- 
toxin amounts which were added to plasma were nearly 
100 times higher than those ones found in human 
disease. So our results possibly only reflect an 
unspecific mechanism occurring when the endogenous 
and pathophysiologically more important specific 
neutralizing activity is exhausted. Nevertheless, there 
could be a therapeutic implication if also in in vivo ex- 
periments an antiendotoxin effect of LDL can be ob- 
served. Our results, together with the former study of 
Flegel et al. should justify animal experiments to 
elucidate the anti-endotoxin process in plasma, in order 
to develop a specific anti-endotoxin therapy in the 
future, which is one of the most urgent problems of in- 
tensive care medicine. 
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